| Date Filed | Type | Description |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/24/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/24/2023 |
8-K
| Quarterly results |
| 03/15/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/10/2023 |
4
| Schuetz Thomas J. (CEO) has filed a Form 4 on Compass Therapeutics, Inc.|
Txns:
| Bought 10,000 shares
@ $3.37, valued at
$33.7k
|
|
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/27/2023 |
4
| Schuetz Thomas J. (CEO) has filed a Form 4 on Compass Therapeutics, Inc.|
Txns:
| Bought 20,000 shares
@ $3.98, valued at
$79.6k
|
|
| 02/24/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 4.2% stake in Compass Therapeutics, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 02/10/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
4
| Chiniara Ellen (Director) has filed a Form 4 on Compass Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $3.93, valued at
$157.2k
|
|
| 02/09/2023 |
4
| GRAY MARY ANN (Director) has filed a Form 4 on Compass Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $3.93, valued at
$157.2k
|
|
| 02/09/2023 |
4
| GORDON CARL L (10% Owner) has filed a Form 4 on Compass Therapeutics, Inc.|
Txns:
| Granted 60,000 options to buy
@ $3.93, valued at
$235.8k
|
|
| 02/09/2023 |
4
| Ferneau Philip (Director) has filed a Form 4 on Compass Therapeutics, Inc.|
Txns:
| Granted 50,000 options to buy
@ $3.93, valued at
$196.5k
|
|
| 02/09/2023 |
4
| Schuetz Thomas J. (CEO) has filed a Form 4 on Compass Therapeutics, Inc.|
Txns:
| Granted 500,000 shares
@ $0
Granted 700,000 options to buy
@ $3.93, valued at
$2.8M
|
|
| 02/09/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 5% stake in COMPASS THERAPEUTICS INC |
| 01/31/2023 |
4
| Schuetz Thomas J. (CEO) has filed a Form 4 on Compass Therapeutics, Inc.|
Txns:
| Bought 20,000 shares
@ $4.05, valued at
$81k
|
|
| 01/24/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 01/24/2023 |
4
| Schuetz Thomas J. (CEO) has filed a Form 4 on Compass Therapeutics, Inc.|
Txns:
| Bought 20,000 shares
@ $4.19, valued at
$83.8k
|
|
| 01/23/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/19/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/02/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 11/29/2022 |
8-K
| Quarterly results |
|